Arfan G, Ong CYF, Ng SMS, et al. Designing an ultra‐short antibacterial peptide with potent activity against Mupirocin‐resistant MRSA. Chem Biol Drug Des. 2018;00:1–8. https://doi.org/10.1111/cbdd.13377
Staphylococcus aureus is the pathogen responsible for the majority of human skin infections. In particular, the Meticillin-resistant variety, MRSA, has become a global clinical concern. The extensive use of Mupirocin, the first-line topical antibacterial drug of choice, has led to the emergence of Mupirocin-resistant MRSA globally, resulting in the urgent need for a replacement. Antimicrobial peptides are deemed plausible candidates. Herein, we describe a structure-activity relationship approach in the design of an ultra-short peptide with potent anti-MRSA activity with a rapid, bactericidal mode of action. Coupled to a low cytotoxic activity, we believe our lead compound can be developed into a topical antibacterial agent to replace Mupirocin as the first-line drug for treating MRSA skin infections.
Agency for Science, Technology and Research (A*STAR) Biomedical Research Council
This is the peer reviewed version of the following article: Arfan G, Ong CYF, Ng SMS, et al. Designing an ultra‐short antibacterial peptide with potent activity against Mupirocin‐resistant MRSA. Chem Biol Drug Des. 2018;00:1–8. https://doi.org/10.1111/cbdd.13377, which has been published in final form at https://doi.org/10.1111/cbdd.13377. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.